Entrada Therapeutics Inc (TRDA) - Net Assets
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has net assets worth $340.72 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($412.90 Million) and total liabilities ($72.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TRDA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $340.72 Million |
| % of Total Assets | 82.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.42 |
Entrada Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore TRDA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Entrada Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see Entrada Therapeutics Inc (TRDA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $428.68 Million | +76.88% |
| 2023-12-31 | $242.36 Million | +14.02% |
| 2022-12-31 | $212.55 Million | -28.84% |
| 2021-12-31 | $298.72 Million | +819.98% |
| 2020-12-31 | $-41.49 Million | -167.37% |
| 2019-12-31 | $-15.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entrada Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11335600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $-43.00K | -0.01% |
| Other Components | $558.06 Million | 130.18% |
| Total Equity | $428.68 Million | 100.00% |
Entrada Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Entrada Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dave & Buster’s Entertainment
NASDAQ:PLAY
|
$403.33 Million |
|
Pharmaniaga Bhd
KLSE:7081
|
$403.33 Million |
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SHE:002566
|
$403.41 Million |
|
Zhejiang Renzhi Co Ltd
SHE:002629
|
$403.41 Million |
|
Shanghai No1 Pharmacy Co Ltd
SHG:600833
|
$403.16 Million |
|
Hanwha Galleria Corp.
KO:452260
|
$403.15 Million |
|
Hu Lane Associate
TWO:6279
|
$403.09 Million |
|
Jiangsu Xinri E-Vehicle Co Ltd
SHG:603787
|
$402.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entrada Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 242,360,000 to 428,678,000, a change of 186,318,000 (76.9%).
- Net income of 65,626,000 contributed positively to equity growth.
- Share repurchases of 574,000 reduced equity.
- New share issuances of 99,608,000 increased equity.
- Other comprehensive income decreased equity by 238,000.
- Other factors increased equity by 21,896,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $65.63 Million | +15.31% |
| Share Repurchases | $574.00K | -0.13% |
| Share Issuances | $99.61 Million | +23.24% |
| Other Comprehensive Income | $-238.00K | -0.06% |
| Other Changes | $21.90 Million | +5.11% |
| Total Change | $- | 76.88% |
Book Value vs Market Value Analysis
This analysis compares Entrada Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-14.81 | $14.50 | x |
| 2020-12-31 | $-1.33 | $14.50 | x |
| 2021-12-31 | $9.57 | $14.50 | x |
| 2022-12-31 | $6.79 | $14.50 | x |
| 2023-12-31 | $7.33 | $14.50 | x |
| 2024-12-31 | $10.99 | $14.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entrada Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.31%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.13%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.23x
- Recent ROE (15.31%) is above the historical average (-7.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.37 Million |
| 2021 | -16.76% | 0.00% | 0.00x | 1.02x | $-79.94 Million |
| 2022 | -41.15% | -346.23% | 0.10x | 1.19x | $-108.71 Million |
| 2023 | -2.76% | -5.18% | 0.27x | 1.94x | $-30.92 Million |
| 2024 | 15.31% | 31.13% | 0.40x | 1.23x | $22.76 Million |
Industry Comparison
This section compares Entrada Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entrada Therapeutics Inc (TRDA) | $340.72 Million | 0.00% | 0.21x | $403.21 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more